Emergent BioSolutions (STU:ER4) Total Stockholders Equity : €611 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Emergent BioSolutions Total Stockholders Equity?

Emergent BioSolutions's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €611 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Emergent BioSolutions's Book Value per Share for the quarter that ended in Mar. 2024 was €11.66. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Emergent BioSolutions's Debt-to-Equity for the quarter that ended in Mar. 2024 was 1.36.

Emergent BioSolutions Total Stockholders Equity Historical Data

The historical data trend for Emergent BioSolutions's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emergent BioSolutions Total Stockholders Equity Chart

Emergent BioSolutions Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

979.65

1,189.43

1,426.18

1,309.99

595.41

Emergent BioSolutions Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															1,123.23	882.67	653.28	595.41	610.79

Emergent BioSolutions (STU:ER4) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Emergent BioSolutions's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(610.788	-	0)	/	52.4
	=	11.66

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Emergent BioSolutions's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(422.464	+	410.964)	/	610.788
	=	1.36

Emergent BioSolutions Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Emergent BioSolutions's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Emergent BioSolutions (STU:ER4) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emergent BioSolutions Inc (STU:ER4) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

EBS:USA ER4:Germany

Address

400 Professional Drive, Suite 400, Gaithersburg, MD, USA, 20879

Website

https://www.emergentbiosolutions.com

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccines, devices, and therapeutic products. The company operates in two reportable segments; the Products Segment and the Services Segment.

Emergent BioSolutions (STU:ER4) Headlines

No Headlines